BI
Bioton S.a.
BIO.WA · WSE
3.45 zł -1.57% (-0.06 zł)
1M -8.38%
Market Cap 294.9M zł
P/E Ratio 72.81x
Div. Yield -
ROE 0.69%
Bulios Fair Price
4.36 zł
26.6% upside
Current Price
3.45 zł
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIO.WA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
49 /100
Fair P/E 72.81x
EV/EBITDA 7.28x
P/FCF 352.80x
Growth
51 /100
Stable EPS growth 33.77%
Rev. growth 6.61%
Book val. growth 0.67%
Profitability
26 /100
Weak Gross margin 35.79%
Net margin 1.52%
FCF margin 0.31%
Quality
6 /100
Poor ROIC 0.90%
ROE 0.69%
Asset turnover 0.35x
Debt
75 /100
Low Debt/Equity 0.10x
Current ratio 1.35x
Net debt/EBITDA 1.16x
Stability
13 /100
Unstable Beta 0.17x
Rev. volatility 29.36%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIO.WA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jeremy Launders
Employees
361
Headquarters
Ozarów Mazowiecki